ライフサイエンスコーパス: hypersensitivity reaction

1 re, life-threatening generalized or systemic hypersensitivity reaction'.

2 S) is an acute, potentially life-threatening hypersensitivity reaction.

3 ch reduces an oxazolone-induced delayed type hypersensitivity reaction.

4 ent one of the most important causes of food hypersensitivity reaction.

5 entally induced peritonitis and delayed-type hypersensitivity reaction.

6 Anaphylaxis is a rapid, life-threatening hypersensitivity reaction.

7 ches for prevention of this potential deadly hypersensitivity reaction.

8 inhibition of ear swelling in a delayed-type hypersensitivity reaction.

9 genome-wide analysis of abacavir-associated hypersensitivity reaction.

10 ion seems to be more of an antibody-mediated hypersensitivity reaction.

11 MHC variant peptide does not induce an acute hypersensitivity reaction.

12 ng the effector phase of the classic type IV hypersensitivity reaction.

13 e treating physician to the possibility of a hypersensitivity reaction.

14 One participant who received TMP-SMX had a hypersensitivity reaction.

15 Anaphylaxis is a life-threatening hypersensitivity reaction.

16 ducing ADRs, especially those caused by drug hypersensitivity reactions.

17 are among the most prevalent drugs inducing hypersensitivity reactions.

18 tion, and the inhibition of antigen-specific hypersensitivity reactions.

19 ure of biotherapeutic treatments and adverse hypersensitivity reactions.

20 nical setting will help to avoid severe drug hypersensitivity reactions.

21 odifying their clearance and may account for hypersensitivity reactions.

22 a higher frequency and severity of immediate hypersensitivity reactions.

23 ted with a chronic inflammatory response and hypersensitivity reactions.

24 ls is critical for the induction of allergic hypersensitivity reactions.

25 n the occurrence of self-reported penicillin hypersensitivity reactions.

26 he mechanisms underlying IgE-mediated type I hypersensitivity reactions.

27 the dermis and potentiate local or systemic hypersensitivity reactions.

28 include information about the possibility of hypersensitivity reactions.

29 amount importance for the evaluation of drug hypersensitivity reactions.

30 and reportedly associated with IgE-mediated hypersensitivity reactions.

31 biotics in the UK and the commonest cause of hypersensitivity reactions.

32 ion has been well documented in delayed drug hypersensitivity reactions.

33 tis, asthma, anaphylaxis, and immediate-type hypersensitivity reactions.

34 he initiation of thrombosis and edema during hypersensitivity reactions.

35 the late elicitation phase of human type IV hypersensitivity reactions.

36 ormal T cell priming and normal delayed-type hypersensitivity reactions.

37 d other examples of IgE-associated immediate hypersensitivity reactions.

38 subjects triggers immediate non-IgE-mediated hypersensitivity reactions.

39 Three percent (n=18) had severe hypersensitivity reactions.

40 re needed to induce substantial delayed-type hypersensitivity reactions.

41 bind to cellular macromolecules and initiate hypersensitivity reactions.

42 ers in the vicinity of HLA-B associated with hypersensitivity reactions.

43 osemide, giving rise to possible allergic or hypersensitivity reactions.

44 be essential for development of delayed-type hypersensitivity reactions.

45 ment with sulfamethoxazole (SMX) can lead to hypersensitivity reactions.

46 ccessfully reduced the incidence of abacavir hypersensitivity reactions.

47 inflammation, are the main triggers of drug hypersensitivity reactions.

48 s, naive mice receiving ASNase ICs developed hypersensitivity reactions.

49 emerged on the pathogenesis of delayed drug hypersensitivity reactions.

50 cereals (wheat, rye and barley) can trigger hypersensitivity reactions.

51 tors (PPIs) have been known to induce type I hypersensitivity reactions.

52 lar in the two trial groups, with no notable hypersensitivity reactions.

53 cause of medical decision and not because of hypersensitivity reactions.

54 ent dual-modality to interfere with allergic hypersensitivity reactions.

55 ith wild-type littermates after delayed-type hypersensitivity reactions.

56 enicillin skin tests (n = 295), only 1 had a hypersensitivity reaction (0.3%; 95% CI, .06%-1.9%), and

57 thologic risk factors for LST were: 1) local hypersensitivity reaction; 2) ostial and/or bifurcation

58 s; 5.0 for nausea; 4.1 for headache; 3.1 for hypersensitivity reactions; 2.6 for urticaria; 0.2 for v

59 wing: grade 4 neutropenia (64% of patients); hypersensitivity reactions (34%, none requiring disconti

60 sea (11%), fever (8%), vomiting (8%), severe hypersensitivity reactions (8%), and diarrhea (8%).

61 83 expression resulted in aggravated contact hypersensitivity reaction accompanied by enhanced CD4(+)

62 pants were aged 7-16 years with an immediate hypersensitivity reaction after peanut ingestion, positi

63 Furthermore, among those with a prior hypersensitivity reaction after the receipt of a sulfona

64 Three patients developed a delayed hypersensitivity reaction after vaccination.

65 ced a case of 10-year-old girl who developed hypersensitivity reactions after eating enokitake.

66 dertook the review of all available cases of hypersensitivity reactions after placement of a drug-elu

67 od and Drug Administration (FDA) reported 50 hypersensitivity reactions after stent placement but lat

68 Acute schistosomiasis is a systemic hypersensitivity reaction against the migrating schistos

69 lobulin E (IgE) and its key role in allergic hypersensitivity reactions against normally harmless sub

70 Clinical monitoring and management of hypersensitivity reactions among patients receiving abac

71 uggestive history of a PPI-induced immediate hypersensitivity reaction and 30 control subjects were i

72 One patient experienced a hypersensitivity reaction and developed non-neutralizing

73 mulated in the skin during the acute contact hypersensitivity reaction and gave rise to epidermal CD8

74 bit increased inflammation in a delayed-type hypersensitivity reaction and increased susceptibility t

75 encephalomyelitis, and had defective contact hypersensitivity reaction and local Ag-induced responses

76 Mast cells play a central role in type I hypersensitivity reactions and allergic disorders such a

77 Many forms of hypersensitivity reactions and allergic responses depend

78 study was to detect ASNase ICs in mice after hypersensitivity reactions and determine their role in h

79 nd control mice developed comparable contact hypersensitivity reactions and imiquimod-triggered psori

80 t only important effector cells in immediate hypersensitivity reactions and immune responses to patho

81 are known to have distinct roles in allergic hypersensitivity reactions and in the immune response to

82 s derived from HAART-related liver toxicity, hypersensitivity reactions and lactic acidosis are recog

83 unity plays a role in late phases of type IV hypersensitivity reactions and may be responding to self

84 n require a range of assays from traditional hypersensitivity reactions and microbe specific immunogl

85 drawbacks, including delayed healing, local hypersensitivity reactions and neoatherosclerosis, which

86 group 2 gadolinium-based contrast agents for hypersensitivity reactions and nephrogenic systemic fibr

87 nosis of proton pump inhibitor (PPI)-induced hypersensitivity reactions and the cross-reactivity betw

88 ng in the diagnosis of PPI-related immediate hypersensitivity reactions and the cross-reactivity patt

89 nvestigation of immediate-type perioperative hypersensitivity reactions and to provide practical info

90 pisode of postural hypotension, one systemic hypersensitivity reaction, and grade 4 transaminitis in

91 s myocarditis, myocardial rupture, neoplasm, hypersensitivity reaction, and immune sensitization (90

92 the prevalence of NSAID-induced respiratory hypersensitivity reactions, and association with chronic

93 (myocarditis, myocardial rupture, neoplasm, hypersensitivity reactions, and immune sensitization).

94 gainst intracellular pathogens, delayed-type hypersensitivity reactions, and induction of organ-speci

95 f pathologies, including autoimmune disease, hypersensitivity reactions, and sepsis.

96 se events-including metabolic complications, hypersensitivity reactions, anemia, and liver enzyme abn

97 Delayed-type, T cell-mediated, drug hypersensitivity reactions are a serious unwanted manife

98 Drug hypersensitivity reactions are an important clinical pro

99 Hypersensitivity reactions are frequent but do not preve

100 idence that some exanthematous allergic drug hypersensitivity reactions are mediated by drug-specific

101 Perioperative immediate hypersensitivity reactions are rare.

102 A) is a common, potentially life-threatening hypersensitivity reaction associated with (1) a specific

103 We report hypersensitivity reactions associated with fidaxomicin,

104 ffeensis, the animals developed delayed-type hypersensitivity reactions at cutaneous sites of the DNA

105 acute lymphoblastic leukemia (ALL); however, hypersensitivity reactions can lead to suboptimal aspara

106 xis, a rare and potentially life-threatening hypersensitivity reaction, can occur after vaccination.

107 ties have been documented, including emesis, hypersensitivity reactions, cardiovascular events, neuro

108 is local reaction, which is likely an Arthus hypersensitivity reaction caused by high levels of antib

109 ospitals who had experienced a perioperative hypersensitivity reaction clinically suggesting anaphyla

110 Administration of carbamazepine (CBZ) causes hypersensitivity reactions clinically characterized by s

111 ed arterial segments with a severe localized hypersensitivity reaction consisting predominantly of T

112 The levels of ASNase ICs detected after hypersensitivity reactions correlated with reaction seve

113 in many tissues, renin release in immediate hypersensitivity reactions could result in local angiote

114 unology (EAACI) differentiates between cross-hypersensitivity reactions (CRs), associated with COX-1

115 These toxicities include infusion or hypersensitivity reactions, cytokine release syndrome, p

116 ich objective signs/symptoms of an immediate hypersensitivity reaction developed) determined by food

117 MDH) is used to describe persons with a drug hypersensitivity reaction (DHR) to at least two chemical

118 Drug hypersensitivity reactions (DHR) are based on distinct m

119 However, severe delayed-type hypersensitivity reactions (DHR) induced by PPI, such as

120 Drug hypersensitivity reactions (DHRs) are a matter of great

121 Drug hypersensitivity reactions (DHRs) are associated with hi

122 Drug hypersensitivity reactions (DHRs) are common, and the sk

123 Drug hypersensitivity reactions (DHRs) are nowadays the third

124 sembling allergy occur, they are called drug hypersensitivity reactions (DHRs) before showing the evi

125 Despite their low frequency, drug hypersensitivity reactions (DHRs) can be serious and res

126 A correct diagnosis of drug hypersensitivity reactions (DHRs) is very important for

127 Drug hypersensitivity reactions (DHRs) represent growing heal

128 adverse reactions-collectively known as drug hypersensitivity reactions (DHRs).

129 f mice with cOVA-induced airway delayed-type hypersensitivity reaction (DTHR) but not into pulmonary

130 The CSD is hypersensitivity reaction due to exposure to complex mot

131 n about the diagnosis and management of drug hypersensitivity reactions due to current and candidate

132 egarding the risks of rare but serious acute hypersensitivity reactions during fast high-dose injecti

133 Hypersensitivity reactions during receipt of antibiotic

134 nd a possible cause of the high incidence of hypersensitivity reactions during the first application

135 on was observed, thus minimizing the risk of hypersensitivity reaction following vaccination with Sm-

136 ions, and differentiating possible localized hypersensitivity reactions from systemic disease are are

137 ts; only 1 of 51 subjects who did not have a hypersensitivity reaction had such antibodies (P<0.001).

138 of patients with severe immune-mediated drug hypersensitivity reactions have tendencies to develop mu

139 A high incidence of moderate to severe hypersensitivity reactions (HRs) is noted in patients wh

140 essee (TN) treated with cetuximab experience hypersensitivity reactions (HSR) at a much higher rate t

141 agement of patients with carboplatin-induced hypersensitivity reactions (HSR) has been complicated by

142 HIV-1 antiretroviral with treatment-limiting hypersensitivity reactions (HSRs) associated with multip

143 The immunological mechanisms driving delayed hypersensitivity reactions (HSRs) to drugs mediated by d

144 Hypersensitivity reactions (HSRs) to intravenous iron pr

145 The optimal approach to patients with hypersensitivity reactions (HSRs) to taxanes has not bee

146 t of concerns for potential infusion-related hypersensitivity reactions (HSRs), initial phase I trial

147 tibiotic-induced eosinophilia and subsequent hypersensitivity reactions (HSRs).

148 e in the number of associated occurrences of hypersensitivity reactions (HSRs).

149 Immediate drug hypersensitivity reactions (IDHR) to moxifloxacin consti

150 Immune-mediated drug hypersensitivity reactions (IDHRs) represent a significa

151 In immediate hypersensitivity reactions, IgE effector function requir

152 sts on the diagnostic approach for immediate hypersensitivity reactions (IHR) to radiocontrast media

153 bout the diagnostic approaches for immediate hypersensitivity reactions (IHRs) due to 5-nitroimidazol

154 ulipid also appeared to cause a dermatologic hypersensitivity reaction in some patients.

155 In a delayed-type hypersensitivity reaction in vivo, compound 211 abolishe

156 cribes the incidence and impact of aprotinin hypersensitivity reactions in children undergoing cardio

157 are among the most commonly encountered drug hypersensitivity reactions in clinical practice.

158 formed a literature search on immediate drug hypersensitivity reactions in clonal MC disorders using

159 e innate immune signaling and promote airway hypersensitivity reactions in diseases such as asthma.

160 r 2-hydroxyethyl methacrylate (HEMA) induces hypersensitivity reactions in humans are not well-establ

161 Abacavir is associated with hypersensitivity reactions in individuals positive for t

162 dysfunction is a key regulator of cutaneous hypersensitivity reactions in obese mice.

163 host-related impurities, which could trigger hypersensitivity reactions in patients with rabbit aller

164 amage to the pulp cells and the induction of hypersensitivity reactions in patients.

165 hanism for the generation and persistence of hypersensitivity reactions in patients.

166 led as drug allergic as the investigation of hypersensitivity reactions in pregnancy is complex and d

167 an T cells in vitro and reduces delayed-type hypersensitivity reactions in rats in vivo.

168 also termed delayed-type or T cell-mediated) hypersensitivity reactions in response to protein-derive

169 Contact hypersensitivity reactions in response to various contac

170 gE Abs and supported a role for IgE-mediated hypersensitivity reactions in sensitized animals followi

171 frequent in these patients, and delayed-type hypersensitivity reactions in the arterial walls of the

172 lish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.

173 can trigger immediate (within minutes) local hypersensitivity reactions in the intestine followed by

174 ocular nerve involvement due to leprosy, and hypersensitivity reactions in tuberculosis.

175 rated during various IgE-dependent immediate hypersensitivity reactions in vivo.

176 TIGIT-Fc inhibited delayed-type hypersensitivity reactions in wild-type but not interleu

177 Molecules that are necessary for ocular hypersensitivity reactions include the receptors CCR1 an

178 In pregnancy, acute drug-induced hypersensitivity reactions including anaphylaxis can hav

179 ociated with a variety of immune-mediated or hypersensitivity reactions, including immediate (type I)

180 hanisms proposed in the pathogenesis of drug hypersensitivity reactions, including the hapten hypothe

181 C3a and C5a as potential effectors in Type 1 hypersensitivity reactions, including urticaria, rhiniti

182 y activated T cells home to the delayed type hypersensitivity reaction induced by the ova.

183 The percentages of patients with hypersensitivity reactions, infusion-related reactions,

184 Gell and Coombs classified hypersensitivity reactions into four 'types'.

185 that UVB-mediated inhibition of delayed-type hypersensitivity reactions is mediated, in part, by the

186 Currently, desensitization in delayed hypersensitivity reactions is restricted to mild, uncomp

187 in some rare instances, serious drug-induced hypersensitivity reactions, largely to the sulfapyridine

188 Safety was measured as the incidence of hypersensitivity reactions, major bleeding, and thromboc

189 syndrome (AGS) describes a wide spectrum of hypersensitivity reactions mediated by specific IgE to t

190 bodies responsible for induction of reaginic hypersensitivity reactions might have unique structures

191 Dose-limiting toxicities (DLTs) were grade 3 hypersensitivity reaction (n = 1) and neutropenic fever

192 tic acid adverse events, including immediate hypersensitivity reactions, NSF, and intracranial gadoli

193 17 studies reporting 14 850 administrations, hypersensitivity reactions occurred in 0.3% (31 of 14 85

194 No hypersensitivity reactions occurred with ABI-007 despite

195 Allergy is an acquired hypersensitivity reaction of the immune system mediated

196 ls through FcepsilonRI and trigger immediate hypersensitivity reactions on antigen encounter.

197 (odds ratio [OR] 9.47, [1.17 to 76.78]) and hypersensitivity reactions (OR 8.91, [1.04 to 76.03]).

198 After a neutralizing hypersensitivity reaction, patients were started with 20

199 Hypersensitivity reaction rate after allergy skin testin

200 Hypersensitivity reaction rate after switching GBCAs was

201 nges, and the inhibition of antigen-specific hypersensitivity reactions, relapsing experimental autoi

202 of patients had capillary leak syndrome and hypersensitivity reactions, respectively.

203 ed with delayed arterial healing and polymer hypersensitivity reactions resulting in chronic inflamma

204 ardized, in vivo diagnostic test for type IV hypersensitivity reactions, resulting in allergic contac

205 strated to play a key role in type II immune hypersensitivity reactions, resulting in the destruction

206 intraocular hemorrhage, traumatic cataract, hypersensitivity reactions, stroke, myocardial infarctio

207 ntibodies are known for triggering immediate hypersensitivity reactions such as food anaphylaxis.

208 Absence of hypersensitivity reactions, superior resistance profile

209 A delayed-type hypersensitivity reaction test was administered on day 2

210 ten challenges reportedly produce a Th2-like hypersensitivity reaction (Th2-like HR).

211 Anaphylaxis is a severe, systemic hypersensitivity reaction that can be potentially life-t

212 Anaphylaxis is a severe systemic hypersensitivity reaction that is rapid in onset; charac

213 Results: Two cases are reported of drug hypersensitivity reaction that were treated with cyclosp

214 various food items, with consequent risk of hypersensitivity reactions that are often severe.

215 iagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur du

216 ches carry additional risk for toxicities or hypersensitivity reactions that can result from covalent

217 the capacity to mount cutaneous delayed type hypersensitivity reactions that disappeared during the d

218 Small immune complexes cause type III hypersensitivity reactions that frequently result in tis

219 ES may be a cause of systemic and intrastent hypersensitivity reactions that, in some cases, have bee

220 For certain HLA allele-associated drug hypersensitivity reactions, the parent drug has been sho

221 In some HLA-associated drug hypersensitivity reactions, the presence of a risk allel

222 The remaining patient developed a hypersensitivity reaction, thus underlining the need to

223 nt adverse effects of contrast media include hypersensitivity reactions, thyroid dysfunction, and con

224 tions (N = 12), the incidence of any type of hypersensitivity reaction to a carbapenem was 3/12 (25%)

225 838), the incidence of any type of suspected hypersensitivity reaction to a carbapenem was 36/838 (4.

226 Conclusion Patients with a prior hypersensitivity reaction to a gadolinium-based contrast

227 of a penicillin among patients with a prior hypersensitivity reaction to a sulfonamide antibiotic, a

228 nd potentially fatal IgE-dependent immediate hypersensitivity reaction to apparently harmless antigen

229 r 1996 and July 2015 for a suspicion of drug hypersensitivity reaction to BLs, with negative ST and p

230 In most subjects who had a hypersensitivity reaction to cetuximab, IgE antibodies a

231 Seven patients (5%) developed a grade 3 or 4 hypersensitivity reaction to cetuximab.

232 the small intestine caused by an immunologic hypersensitivity reaction to dietary wheat gluten.

233 We describe a delayed hypersensitivity reaction to Jorveza(R), a newly develop

234 Fifteen of the 31 patients with a hypersensitivity reaction to lansoprazole had a positive

235 ubjects who are able to mount a delayed type hypersensitivity reaction to M. tuberculosis.

236 etween 1997 and 2017 for a suspicion of drug hypersensitivity reaction to NSAIDs.

237 Ten percent developed a neutralizing hypersensitivity reaction to PEGasparaginase, of which 4

238 on provide the signals necessary to induce a hypersensitivity reaction to SMX.

239 mong 76 cetuximab-treated subjects, 25 had a hypersensitivity reaction to the drug.

240 case report describes a patient with severe hypersensitivity reaction to vancomycin who successfully

241 ngs suggest that HORV is caused by a delayed hypersensitivity reaction to vancomycin.

242 ions, whereas three patients developed cross-hypersensitivity reactions to alternative structurally s

243 Hypersensitivity reactions to aprotinin have been report

244 The risk of hypersensitivity reactions to aprotinin is low in childr

245 Patients with an ACS and histories of hypersensitivity reactions to ASA, especially following

246 with stable CIHD and histories of nonsevere hypersensitivity reactions to ASA/NSAIDs, an ASA challen

247 Hypersensitivity reactions to aspirin (acetylsalicylic a

248 Posttreatment induction of delayed-type hypersensitivity reactions to autologous leukemia cells

249 ociations have been discovered for immediate hypersensitivity reactions to beta-lactams, aspirin, and

250 was identified in 268 patients with delayed hypersensitivity reactions to beta-lactams.

251 A high prevalence of hypersensitivity reactions to cetuximab has been reporte

252 number of patients show immediate selective hypersensitivity reactions to clavulanic acid (CLV) and

253 udoallergy (CARPA) in pigs, a model of human hypersensitivity reactions to Doxil.

254 Hypersensitivity reactions to drugs are often unpredicta

255 Patients have developed delayed-type hypersensitivity reactions to E75 postvaccination compar

256 atients with a clinical history of immediate hypersensitivity reactions to either penicillins or ceph

257 ome of the research advances in anaphylaxis; hypersensitivity reactions to foods, drugs, and insects;

258 ome of the research advances in anaphylaxis; hypersensitivity reactions to foods, drugs, and insects;

259 ome of the research advances in anaphylaxis; hypersensitivity reactions to foods, drugs, and insects;

260 ome of the research advances in anaphylaxis; hypersensitivity reactions to foods, drugs, and insects;

261 Background Hypersensitivity reactions to gadolinium-based contrast

262 ent mice, moreover, developed weaker contact hypersensitivity reactions to haptens applied epicutaneo

263 Nonimmediate hypersensitivity reactions to iodinated contrast media (

264 n stimulated the development of delayed-type hypersensitivity reactions to irradiated, dissociated, a

265 n stimulated the development of delayed-type hypersensitivity reactions to irradiated, dissociated, a

266 because many individuals develop cutaneous, hypersensitivity reactions to mosquito saliva after repe

267 BACKGROUND/AIM: The consensus document for hypersensitivity reactions to nonsteroidal anti-inflamma

268 A total of 370 patients with a history of hypersensitivity reactions to NSAIDs among the 1250 outp

269 In five patients (1.6%), the hypersensitivity reactions to NSAIDs did not meet the EN

270 ions and clinically useful classification of hypersensitivity reactions to NSAIDs.

271 mice failed to mount T cell and delayed type hypersensitivity reactions to OVA, suggesting that the T

272 We found that contact hypersensitivity reactions to oxazolone in mice were ass

273 HLA-DRB1*10:01 predisposed to immediate hypersensitivity reactions to penicillins.

274 l method for the diagnosis of immediate-type hypersensitivity reactions to PPIs and for the evaluatio

275 Severe hypersensitivity reactions to red meat with delay of sev

276 have identified strong linkages between drug hypersensitivity reactions to several drugs and specific

277 issued a warning of subacute thrombosis and hypersensitivity reactions to sirolimus-eluting stents (

278 ort a very low incidence of acute or delayed hypersensitivity reactions to the antivenom.

279 adults in the United States now affected by hypersensitivity reactions to various foods.

280 e 3 toxicity included emesis, increased ALT, hypersensitivity reactions (two patients each), and drug

281 not associated with any manifestations of a hypersensitivity reaction upon readministration of the t

282 en SARS or MERS vaccines resulted in vaccine hypersensitivity reactions (VAH), similar to those in hu

283 During IgE-mediated immediate hypersensitivity reactions, vascular endothelial cells p

284 n age 42.12 +/- 13.24), the leading cause of hypersensitivity reactions was metamizol (30.5%) followe

285 trol of cutaneous inflammation, delayed-type hypersensitivity reactions were elicited in the ear skin

286 Thirteen (2.5%) of 552 patients experiencing hypersensitivity reactions were exposed to a BL during t

287 No severe hypersensitivity reactions were reported despite the lac

288 teroid premedication was administered and no hypersensitivity reactions were seen.

289 smoking status, and history of NSAID-induced hypersensitivity reactions were sent to participants by

290 Incidences of vomiting and drug-hypersensitivity reactions were significantly higher in

291 her structurally different PPI without cross-hypersensitivity reactions, whereas three patients devel

292 ding of the role of CCL7 in mediating ocular hypersensitivity reactions will provide insights into ma

293 te is high, and it was produced by a delayed hypersensitivity reaction with a Th2 response.

294 xis is a severe potentially life-threatening hypersensitivity reaction with an estimated lifetime pre

295 able reliability for the absence of a severe hypersensitivity reaction with the subsequent drug infus

296 Hypersensitivity reactions with allopurinol and febuxost

297 ndividuals, NSAIDs induce a wide spectrum of hypersensitivity reactions with various timing, organ ma

298 ssociated with a 6%-10% risk of developing a hypersensitivity reaction, with different phenotypes, in

299 e most frequent medicaments involved in drug hypersensitivity reactions, with NSAID-induced urticaria

300 dered when treating patients with a previous hypersensitivity reaction within the same class of antib